STOCK TITAN

Ekso Bionics - EKSO STOCK NEWS

Welcome to our dedicated page for Ekso Bionics news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics stock.

Ekso Bionics Holdings, Inc. (Symbol: EKSO) is a pioneering company in the field of robotic exoskeletons, or wearable robots, aimed at augmenting human strength, endurance, and mobility. Since its founding in 2005, Ekso Bionics has developed cutting-edge technology that has enabled thousands of people with paralysis to take millions of steps that would otherwise be impossible. Headquartered in Richmond, California, with international offices in London, the company has been a leader in both the healthcare and industrial markets.

Ekso Bionics operates through two main segments: EksoHealth and EksoWorks. The EksoHealth segment, which generates the majority of the company's revenue, focuses on designing, engineering, manufacturing, and selling exoskeletons for medical applications. These devices are worn over clothing and controlled by trained operators to assist individuals with mobility challenges. The EksoWorks segment, on the other hand, targets able-bodied users by creating exoskeleton devices that help them perform strenuous, repetitive tasks for extended periods.

Over the years, Ekso Bionics has been at the forefront of innovation, continuously pushing the boundaries of what robotic exoskeletons can achieve. Their products have not only redefined the scope of physical rehabilitation but have also found significant applications in various industrial settings, allowing workers to carry out challenging tasks more efficiently. Ekso Bionics is committed to breaking physical limitations and helping users reach new heights of capability.

For the latest updates, partnerships, and developments related to Ekso Bionics and their stock performance, visit StockTitan regularly.

Rhea-AI Summary

Ekso Bionics has announced a research partnership with Shepherd Center, a leading rehabilitation hospital in Atlanta. The collaboration aims to integrate EksoNR and Ekso Indego devices into rehabilitation and community settings to enhance patient quality of life. Ekso and Shepherd Center will co-develop a research and training program for these devices, focusing on best practices for their clinical and individual use. This initiative follows the Centers for Medicare & Medicaid Services' recent decision to provide reimbursement for the Ekso Indego Personal device, increasing accessibility for spinal cord injury patients. Shepherd Center's expertise in spinal cord injuries will play a key role in evaluating the benefits of exoskeleton technology throughout the care continuum.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
partnership
-
Rhea-AI Summary

Ekso Bionics has appointed Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. Scher brings extensive healthcare experience, having served as an Executive Advisor to the U.S. Department of Veterans Affairs (VA). She led the VA Secretary's Center for Strategic Partnerships and implemented over $250 million in programs for veterans. Currently, she is a Senior Advisor at the Milken Institute and serves on multiple boards. Scher's appointment aligns with Ekso's recent Medicare reimbursement pricing for the Ekso Indego Personal, which aids in patient rehabilitation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
management
-
Rhea-AI Summary

Ekso Bionics Holdings, an industry leader in exoskeleton technology, will feature the Ekso Indego Personal on 'Health Uncensored' with Dr. Drew Pinsky on Fox Business News. The episode will air on May 12, showcasing the device's user-reported benefits and advanced technology. The Ekso Indego Personal is a powered exoskeleton designed to help patients with mobility impairments walk independently, offering a potentially life-changing solution for individuals previously confined to wheelchairs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
Rhea-AI Summary

Ekso Bionics reported financial results for the first quarter of 2024, highlighting revenues of $3.8 million and a gross margin of 52%. The company achieved a final payment determination for Medicare reimbursement, sold 29 EksoHealth units, and focused on developing the market for Indego Personal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
-
Rhea-AI Summary
Ekso Bionics, a leader in exoskeleton technology for medical and industrial use, will report its first quarter 2024 financial results on April 29, 2024. The Company will discuss financial results and recent business developments in a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences earnings
-
Rhea-AI Summary
Ekso Bionics Holdings, Inc. announces Medicare reimbursement for Ekso Indego Personal at $91,031.93, effective April 1, 2024. The Healthcare Common Procedure Coding System Code K1007 approved for billing. Ekso Bionics to collaborate with clinics for patient qualification and training.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
Rhea-AI Summary
Ekso Bionics Holdings, Inc. reported record revenue of $18.3 million in 2023, a 42% year-over-year increase. The Company sold 151 EksoHealth units and launched GaitCoach software. Despite a net loss of $15.2 million for the full year, Ekso remains optimistic about long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.76%
Tags
none
-
Rhea-AI Summary
Ekso Bionics Holdings, Inc. (EKSO) will release financial and business results for Q4 and full year 2023 on March 4, 2024. The Company, known for exoskeleton technology, will host a conference call to discuss the results and recent developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences earnings
-
Rhea-AI Summary
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced a securities purchase agreement with institutional investors for the purchase and sale of 2,967,742 shares of common stock at a purchase price of $1.55 per share, resulting in total gross proceeds of approximately $4.6 million before deducting expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
Rhea-AI Summary
Ekso Bionics Holdings, an industry leader in exoskeleton technology for medical and industrial use, announced the launch of GaitCoach™, its next generation gait therapy software for EksoNR. GaitCoach is designed to improve user trust in technology, provide impactful feedback, and offer specific guidance, making the device more intuitive and easier to use for both patients and physical therapists. The software has received positive feedback from experienced users, with 96% finding it intuitive and 93% believing it would be useful for new or less experienced therapists. However, the software is initially available only in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
none

FAQ

What is the current stock price of Ekso Bionics (EKSO)?

The current stock price of Ekso Bionics (EKSO) is $0.5248 as of February 28, 2025.

What is the market cap of Ekso Bionics (EKSO)?

The market cap of Ekso Bionics (EKSO) is approximately 11.4M.

What does Ekso Bionics Holdings, Inc. do?

Ekso Bionics Holdings, Inc. designs, develops, and sells wearable robotic exoskeletons to augment human strength, endurance, and mobility.

Where is Ekso Bionics headquartered?

Ekso Bionics is headquartered in Richmond, California.

What are the main segments of Ekso Bionics?

Ekso Bionics operates through two main segments: EksoHealth and EksoWorks.

What does the EksoHealth segment specialize in?

The EksoHealth segment specializes in designing, engineering, manufacturing, and selling exoskeletons for medical applications.

What does the EksoWorks segment focus on?

The EksoWorks segment focuses on creating exoskeleton devices for able-bodied users to perform repetitive tasks more efficiently.

How has Ekso Bionics impacted people with paralysis?

Ekso Bionics' exoskeletons have helped thousands of people with paralysis take millions of steps that would otherwise be impossible.

In which regions does Ekso Bionics operate?

Ekso Bionics operates in the Americas, EMEA (Europe, Middle East, and Africa), and APAC (Asia-Pacific).

How can I get in touch with Ekso Bionics for investor relations?

For investor relations, you can contact David Carey at 212-867-1768 or via email at investors@eksobionics.com.

What innovations has Ekso Bionics brought to the industrial market?

Ekso Bionics has developed exoskeleton devices that enable workers to carry out difficult, repetitive tasks for extended periods, enhancing efficiency and reducing fatigue.

How does Ekso Bionics contribute to physical rehabilitation?

Ekso Bionics' exoskeletons are used in medical settings to assist individuals with mobility challenges, facilitating physical rehabilitation by aiding movement and strength.
Ekso Bionics

Nasdaq:EKSO

EKSO Rankings

EKSO Stock Data

11.36M
20.03M
7.91%
25.3%
6.66%
Medical Instruments & Supplies
General Industrial Machinery & Equipment, Nec
Link
United States
SAN RAFAEL